Last reviewed · How we verify
F901318 tolerability
At a glance
| Generic name | F901318 tolerability |
|---|---|
| Also known as | adverse events |
| Sponsor | F2G Biotech GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim (PHASE1)
- Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects (PHASE1)
- Pharmacokinetics of IV Formulation (PHASE1)
- Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (PHASE1)
- F901318 Multiple Ascending Dose Study (PHASE1)
- Single Ascending Oral Dose Study of F901318 (PHASE1)
- F901318 Single Ascending Dose Study in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F901318 tolerability CI brief — competitive landscape report
- F901318 tolerability updates RSS · CI watch RSS
- F2G Biotech GmbH portfolio CI